RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85

Rhea-AI Filing Summary

RenovoRx, Inc. director and Chief Medical Officer Ramtin Agah reported buying 12,000 shares of the company’s common stock in an open market transaction on December 16, 2025, at a price of $0.85 per share.

After this purchase, he beneficially owns 778,460 shares of RenovoRx common stock, held directly. Agah serves as both a director and an officer, so this transaction increases his personal equity stake alongside his leadership responsibilities at the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agah Ramtin

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CA 94040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		P		12,000(1)	A	$0.85	778,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an open market purchase of the Issuer's securities.

	/s/ Ramtin Agah	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider share transaction did RenovoRx (RNXT) disclose?

RenovoRx disclosed that director and Chief Medical Officer Ramtin Agah purchased 12,000 shares of the company’s common stock in an open market transaction on December 16, 2025 at a price of $0.85 per share.

Who is the reporting person in the RenovoRx (RNXT) Form 4 and what is their role?

The reporting person is Ramtin Agah, who is identified as both a director and an officer of RenovoRx, Inc., with the officer title of Chief Medical Officer.

How many RenovoRx (RNXT) shares does Ramtin Agah own after the reported transaction?

Following the reported open market purchase, Ramtin Agah beneficially owns 778,460 shares of RenovoRx common stock, with the ownership form reported as direct.

What was the price paid per share in the RenovoRx (RNXT) insider purchase?

For the 12,000 shares of RenovoRx common stock acquired on December 16, 2025, Ramtin Agah paid a reported purchase price of $0.85 per share.

Was the RenovoRx (RNXT) insider transaction an open market purchase or another type of acquisition?

The explanation states that the transaction reflects an open market purchase of RenovoRx’s securities, indicating the shares were bought on the open market rather than through option exercises or other arrangements.

Is the RenovoRx (RNXT) Form 4 filed by one or multiple reporting persons?

The report indicates that the Form 4 is filed by one reporting person, specifically covering the transactions of Ramtin Agah alone.